Kelly Morgan, MS, CGC, on Improving Family Discussions on Genetic Risk for Cancer


The MSK expert explained that pre- and post-test education on genetic testing also improved family discussions about their risk.

Pre- and post-test education on genetic testing may help spark conversations among those who may be at risk for cancer, according to Kelly Morgan, MS, CGC.

In a recent study, presented at the 2020 ASCO Virtual Scientific Program, the BRCA Founder OutReach (BFOR) offered pre-testing online education with posttest engagement of primary care providers, which appeared to be effective in educating both patients and providers alike.

In a recent interview with CancerNetwork, Morgan, genetic counselor at Memorial Sloan Kettering Cancer Center, discussed how using telehealth for genetic testing education can assist in family discussions surrounding cancer risk.


You know, you could imagine, if you will, that a tool like this where people can access medical information that's very detailed from home is something that could lend itself well to being shared with family.

One of the things along those lines that we learned from this study that's very interesting is, I mentioned that about 3.4% of participants tested positive. When we look at that group, over half, so actually over 60%, had a family mutation. So that would suggest that many individuals are taking advantage of this model to go forward with testing for what was already in their family. So we might imagine that this testing might have been primarily up took by individuals who didn't have any known risks and we're hearing about for the first time, but rather, it seems to be a tool that actually lends itself pretty well to spreading genetic test and genetic information within a family.

Related Videos
Howard A. Burris, MD, highlighted previous findings of the phase 3 TOPAZ-1 trial assessing durvalumab plus gemcitabine and cisplatin vs placebo plus gemcitabine and cisplatin in advanced biliary tract cancer and patient-reported outcomes (PRO)data that were presented at 2022 ASCO.
Shubham Pant, MD, spoke to the potential of ELI-002 2P as a treatment for minimal residual disease positivity in patients with KRAS-mutant solid tumors.
Eric J. Sherman, MD, highlights several drugs that are being used to treat RET-positive thyroid cancer.
Eric J. Sherman, MD, on the Efficacy of Cabozantinib in Refractory Differentiated Thyroid Cancer
Eric J. Sherman, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center,
Eric J. Sherman, MD, of Memorial Sloan Kettering Cancer Center highlights research on adjuvant capecitabine in nasopharynx cancer.